Buy Now

Get the Recordings of the Summit Here!

This content is locked

This content is no longer available.

Video content locked

Speaker expertise

Gabby is a clinical psychologist and National Institute on Drug Abuse (NIDA)-funded research fellow at Weill Institute for Neuroscience, Department of Psychiatry, UCSF. She received her PhD in clinical psychology from Palo Alto University. Her doctoral research focused on the clinical applications of psilocybin-assisted therapy and mindful self-compassion-based interventions to treat mood, substance use, and trauma-based disorders. Gabby's work draws on quantitative and qualitative methodologies to explore underlying psychological and neurobiological mechanisms responsible for catalyzing behavioral changes, including emotion regulation, meta-awareness, and pro sociality. Gabby's current research is focused on the use of opioid replacement therapies to treat opioid use disorder and chronic pain. She is also exploring the use of behavioral paradigms to help prevent relapse and restructure dysregulated motivational reward systems involved in addiction.

September 17, 2020, 06:15 PM

Effects and Possible Mechanisms of Psilocybin Therapy Among Patients with Mental Health Problems

A talk by Gabrielle Agin-Liebes PhD, Alan Davis and Gianni Glick
University of California, San Francisco & Johns Hopkins Center for Psychedelic & Conciousness Research

Dr. Alan Davis discusses the long-term effects and possible mechanisms of psilocybin therapy among patients with mental health problems in a 12-month follow-up from the John's Hopkins University clinical trial.

Dr. Gianni Glick explores the potential relationship between social neuroscience, psychological well-being, and inflammatory gene expression, as it relates to the qualitative experience of participants in psilocybin-assisted therapy trials.

Dr. Gabrielle Agin-Liebes discusses the findings of her recently published long-term follow-up analysis of a randomized controlled trial at NYU of psilocybin-assisted psychotherapy results suggest that clinical improvements in anxiety, depression, and existential distress continue to persist up to 4.5 years after psilocybin administration. Dr. Agin-Liebes will further detail the clinical implications of these findings for the field of psycho-oncology and future next steps.

Join the discussion

You need to be registered as an attendee in order to comment on this talk.


Categories covered

Sponsor this Conference

Your logo could go here!

If you'd like to get your brand in front of attendees contact us.